The results of this study suggested that the risk of death in the group with baseline CD4 levels equal to or greater than 200 cells/μL was lower than that in the group with baseline CD4 levels less than 200 cells/μL. The earlier HIV/AIDS patients receive HAART, the more effective the treatment will be. This evidence concerns the gene CD4 and AIDS.